{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:50:38Z","timestamp":1789537838506,"version":"build-2803163510"},"reference-count":55,"publisher":"e-Century Publishing Corporation","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/nrgg6465","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T05:45:34Z","timestamp":1725515134000},"page":"4246-4255","source":"Crossref","is-referenced-by-count":5,"title":["Aldosterone\u2019s impact on kidney health: exploring the benefits of mineralocorticoid receptor antagonists for renal protection"],"prefix":"10.62347","volume":"16","author":[{"given":"Zige","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","article-title":"Chronic kidney disease and the global public health agenda: an international consensus","volume":"20","author":"Francis","year":"2024","unstructured":"Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, Fliser D, Roy-Chaudhury P, Fontana M, Nangaku M, Wanner C, Malik C, Hradsky A, Adu D, Bavanandan S, Cusumano A, Sola L, Ulasi I and Jha V; American Society of Nephrology; European Renal Association; International Society of Nephrology. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol 2024; 20: 473-485.","journal-title":"Nat Rev Nephrol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/CIRCRESAHA.122.321762","article-title":"Hypertension as cardiovascular risk factor in chronic kidney disease","volume":"132","author":"Burnier","year":"2023","unstructured":"Burnier M and Damianaki A. Hypertension as cardiovascular risk factor in chronic kidney disease. Circ Res 2023; 132: 1050-1063.","journal-title":"Circ Res"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Martínez-Montoro JI, Morales E, Cornejo-Pareja I, Tinahones FJ and Fernández-García JC. Obesity-related glomerulopathy: current approaches and future perspectives. Obes Rev 2022; 23: e13450.","DOI":"10.1111\/obr.13450"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Mukoyama M and Kuwabara T. Role of renin-angiotensin system blockade in advanced CKD: to use or not to use? Hypertens Res 2022; 45: 1072-1075.","DOI":"10.1038\/s41440-022-00902-7"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41371-021-00504-9","article-title":"Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction","volume":"35","author":"Loutradis","year":"2021","unstructured":"Loutradis C, Price A, Ferro CJ and Sarafidis P. Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction. J Hum Hypertens 2021; 35: 499-509.","journal-title":"J Hum Hypertens"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41581-019-0248-y","article-title":"Targeting the progression of chronic kidney disease","volume":"16","author":"Ruiz-Ortega","year":"2020","unstructured":"Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A and Rodrigues-Diez RR. Targeting the progression of chronic kidney disease. Nat Rev Nephrol 2020; 16: 269-288.","journal-title":"Nat Rev Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.3390\/ijms24065370","article-title":"The effect of aldosterone on cardiorenal and metabolic systems","volume":"24","author":"Otsuka","year":"2023","unstructured":"Otsuka H, Abe M and Kobayashi H. The effect of aldosterone on cardiorenal and metabolic systems. Int J Mol Sci 2023; 24: 5370.","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10157-023-02413-2","article-title":"The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances","volume":"28","author":"Chen","year":"2024","unstructured":"Chen X, Li X, Zhang K, Lian K, Zhang W, Song Y, Kan C, Zhang J, Han F, Sun X and Guo Z. The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances. Clin Exp Nephrol 2024; 28: 125-135.","journal-title":"Clin Exp Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/17512433.2022.2094770","article-title":"Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes","volume":"15","author":"Lerma","year":"2022","unstructured":"Lerma EV and Wilson DJ. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes. Expert Rev Clin Pharmacol 2022; 15: 501-513.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1055\/a-2054-1062","article-title":"An abbreviated history of aldosterone metabolism, current and future challenges","volume":"131","author":"Gomez-Sanchez","year":"2023","unstructured":"Gomez-Sanchez CE and Gomez-Sanchez EP. An abbreviated history of aldosterone metabolism, current and future challenges. Exp Clin Endocrinol Diabetes 2023; 131: 386-393.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s12020-023-03566-6","article-title":"Extra-adrenal aldosterone: a mini review focusing on the physiology and pathophysiology of intrarenal aldosterone","volume":"83","author":"Xu","year":"2024","unstructured":"Xu C. Extra-adrenal aldosterone: a mini review focusing on the physiology and pathophysiology of intrarenal aldosterone. Endocrine 2024; 83: 285-301.","journal-title":"Endocrine"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"108701","DOI":"10.1016\/j.steroids.2020.108701","article-title":"An overview of the classical and tissue-derived renin-angiotensin-aldosterone system and its genetic polymorphisms in essential hypertension","volume":"163","author":"Abdel Ghafar","year":"2020","unstructured":"Abdel Ghafar MT. An overview of the classical and tissue-derived renin-angiotensin-aldosterone system and its genetic polymorphisms in essential hypertension. Steroids 2020; 163: 108701.","journal-title":"Steroids"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/cvr\/cvy023","article-title":"Vascular smooth muscle contraction in hypertension","volume":"114","author":"Touyz","year":"2018","unstructured":"Touyz RM, Alves-Lopes R, Rios FJ, Camargo LL, Anagnostopoulou A, Arner A and Montezano AC. Vascular smooth muscle contraction in hypertension. Cardiovasc Res 2018; 114: 529-539.","journal-title":"Cardiovasc Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ajh\/hpaa137","article-title":"Aldosterone, inflammation, immune system, and hypertension","volume":"34","author":"Ferreira","year":"2021","unstructured":"Ferreira NS, Tostes RC, Paradis P and Schiffrin EL. Aldosterone, inflammation, immune system, and hypertension. Am J Hypertens 2021; 34: 15-27.","journal-title":"Am J Hypertens"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3390\/jcm11072020","article-title":"An up-to-date article regarding particularities of drug treatment in patients with chronic heart failure","volume":"11","author":"Buda","year":"2022","unstructured":"Buda V, Prelipcean A, Cozma D, Man DE, Negres S, Scurtu A, Suciu M, Andor M, Danciu C, Crisan S, Dehelean CA, Petrescu L and Rachieru C. An up-to-date article regarding particularities of drug treatment in patients with chronic heart failure. J Clin Med 2022; 11: 2020.","journal-title":"J Clin Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1177\/2047487319848105","article-title":"Non-steroidal anti-inflammatory drug effects on renal and cardiovascular function: from physiology to clinical practice","volume":"27","author":"Cabassi","year":"2020","unstructured":"Cabassi A, Tedeschi S, Perlini S, Verzicco I, Volpi R, Gonzi G and Canale SD. Non-steroidal anti-inflammatory drug effects on renal and cardiovascular function: from physiology to clinical practice. Eur J Prev Cardiol 2020; 27: 850-867.","journal-title":"Eur J Prev Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1204598","DOI":"10.1155\/2018\/1204598","article-title":"Aldosterone and mineralocorticoid receptor system in cardiovascular physiology and pathophysiology","volume":"2018","author":"Cannavo","year":"2018","unstructured":"Cannavo A, Bencivenga L, Liccardo D, Elia A, Marzano F, Gambino G, D’Amico ML, Perna C, Ferrara N, Rengo G and Paolocci N. Aldosterone and mineralocorticoid receptor system in cardiovascular physiology and pathophysiology. Oxid Med Cell Longev 2018; 2018: 1204598.","journal-title":"Oxid Med Cell Longev"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/s41588-023-01498-5","article-title":"Somatic SLC30A1 mutations altering zinc transporter ZnT1 cause aldosterone-producing adenomas and primary aldosteronism","volume":"55","author":"Rege","year":"2023","unstructured":"Rege J, Bandulik S, Nanba K, Kosmann C, Blinder AR, Plain A, Vats P, Kumar-Sinha C, Lerario AM, Else T, Yamazaki Y, Satoh F, Sasano H, Giordano TJ, Williams TA, Reincke M, Turcu AF, Udager AM, Warth R and Rainey WE. Somatic SLC30A1 mutations altering zinc transporter ZnT1 cause aldosterone-producing adenomas and primary aldosteronism. Nat Genet 2023; 55: 1623-1631.","journal-title":"Nat Genet"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3390\/ijms24010286","article-title":"Molecular mechanisms of Na-Cl cotransporter in relation to hypertension in chronic kidney disease","volume":"24","author":"Liang","year":"2022","unstructured":"Liang L and Shimosawa T. Molecular mechanisms of Na-Cl cotransporter in relation to hypertension in chronic kidney disease. Int J Mol Sci 2022; 24: 286.","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/bs.vh.2018.09.005","article-title":"Aldosterone and myocardial pathology","volume":"109","author":"Cannavo","year":"2019","unstructured":"Cannavo A, Elia A, Liccardo D, Rengo G and Koch WJ. Aldosterone and myocardial pathology. Vitam Horm 2019; 109: 387-406.","journal-title":"Vitam Horm"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"614279","DOI":"10.3389\/fcvm.2020.614279","article-title":"Cardiac mineralocorticoid receptor and the Na+\/H+ Exchanger: spilling the beans","volume":"7","author":"Ennis","year":"2021","unstructured":"Ennis IL and Pérez NG. Cardiac mineralocorticoid receptor and the Na+\/H+ Exchanger: spilling the beans. Front Cardiovasc Med 2021; 7: 614279.","journal-title":"Front Cardiovasc Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.cjca.2016.02.070","article-title":"Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications","volume":"32","author":"Harvey","year":"2016","unstructured":"Harvey A, Montezano AC, Lopes RA, Rios F and Touyz RM. Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications. Can J Cardiol 2016; 32: 659-668.","journal-title":"Can J Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","article-title":"Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology","volume":"98","author":"Forrester","year":"2018","unstructured":"Forrester SJ, Booz GW, Sigmund CD, Coffman TM, Kawai T, Rizzo V, Scalia R and Eguchi S. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol Rev 2018; 98: 1627-1738.","journal-title":"Physiol Rev"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"DuPont JJ and Jaffe IZ. 30 years of the mineralocorticoid receptor: the role of the mineralocorticoid receptor in the vasculature. J Endocrinol 2017; 234: T67-T82.","DOI":"10.1530\/JOE-17-0009"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41578-021-00381-1","article-title":"A framework for developing sex-specific engineered heart models","volume":"7","author":"Lock","year":"2022","unstructured":"Lock R, Al Asafen H, Fleischer S, Tamargo M, Zhao Y, Radisic M and Vunjak-Novakovic G. A framework for developing sex-specific engineered heart models. Nat Rev Mater 2022; 7: 295-313.","journal-title":"Nat Rev Mater"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"5342161","DOI":"10.1155\/2020\/5342161","article-title":"Comparison of effects of ACEIs and ARBs on albuminuria and hyperkalemia in indonesian hypertensive type 2 diabetes mellitus patients","volume":"2020","author":"Agustina","year":"2020","unstructured":"Agustina PS, Yunir E, Prawiroharjo P, Damanik J and Sauriasari R. Comparison of effects of ACEIs and ARBs on albuminuria and hyperkalemia in indonesian hypertensive type 2 diabetes mellitus patients. Int J Hypertens 2020; 2020: 5342161.","journal-title":"Int J Hypertens"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1161\/01.RES.67.6.1355","article-title":"Remodeling of the rat right and left ventricles in experimental hypertension","volume":"67","author":"Brilla","year":"1990","unstructured":"Brilla CG, Pick R, Tan LB, Janicki JS and Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67: 1355-1364.","journal-title":"Circ Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","article-title":"Aldosterone as a mediator of cardiovascular damage","volume":"79","author":"Buffolo","year":"2022","unstructured":"Buffolo F, Tetti M, Mulatero P and Monticone S. Aldosterone as a mediator of cardiovascular damage. Hypertension 2022; 79: 1899-1911.","journal-title":"Hypertension"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Martín-Fernández B, Rubio-Navarro A, Cortegano I, Ballesteros S, Alía M, Cannata-Ortiz P, Olivares-Álvaro E, Egido J, De Andrés B, Gaspar ML, De Las Heras N, Lahera V and Moreno JA. Aldosterone induces renal fibrosis and inflammatory M1-macrophage subtype via mineralocorticoid receptor in rats. PLoS One 2016; 11: e0145946.","DOI":"10.1371\/journal.pone.0145946"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG and Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-H1810.","DOI":"10.1152\/ajpheart.01096.2001"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10157-011-0498-x","article-title":"Aldosterone stimulates nuclear factor-kappa B activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum- and glucocorticoid-inducible protein kinase-1","volume":"16","author":"Terada","year":"2012","unstructured":"Terada Y, Ueda S, Hamada K, Shimamura Y, Ogata K, Inoue K, Taniguchi Y, Kagawa T, Horino T and Takao T. Aldosterone stimulates nuclear factor-kappa B activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum- and glucocorticoid-inducible protein kinase-1. Clin Exp Nephrol 2012; 16: 81-88.","journal-title":"Clin Exp Nephrol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1177\/1470320313519486","article-title":"Aldosterone-induced inflammatory response of mesangial cells via angiotension II receptors","volume":"16","author":"Hao","year":"2015","unstructured":"Hao J, Ren L, Zhang L, Kong D and Hao L. Aldosterone-induced inflammatory response of mesangial cells via angiotension II receptors. J Renin Angiotensin Aldosterone Syst 2015; 16: 739-748.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3390\/cells8111389","article-title":"The role of inflammasome-dependent and inflammasome-independent NLRP3 in the kidney","volume":"8","author":"Kim","year":"2019","unstructured":"Kim YG, Kim SM, Kim KP, Lee SH and Moon JY. The role of inflammasome-dependent and inflammasome-independent NLRP3 in the kidney. Cells 2019; 8: 1389.","journal-title":"Cells"},{"key":"ref33","unstructured":"Sztechman D, Czarzasta K, Cudnoch-Jedrzejewska A, Szczepanska-Sadowska E and Zera T. Aldosterone and mineralocorticoid receptors in regulation of the cardiovascular system and pathological remodelling of the heart and arteries. J Physiol Pharmacol 2018; 69."},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Shrestha A, Che RC and Zhang AH. Role of aldosterone in renal fibrosis. In: Liu BC, Lan HY, Lv LL, editors. Renal Fibrosis: Mechanisms and Therapies. Singapore: Springer Singapore; 2019. pp. 325-346.","DOI":"10.1007\/978-981-13-8871-2_15"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"6421","DOI":"10.3390\/ijms21176421","article-title":"Oxidative stress, kinase activity and inflammatory implications in right ventricular hypertrophy and heart failure under hypobaric hypoxia","volume":"21","author":"Pena","year":"2020","unstructured":"Pena E, Brito J, El Alam S and Siques P. Oxidative stress, kinase activity and inflammatory implications in right ventricular hypertrophy and heart failure under hypobaric hypoxia. Int J Mol Sci 2020; 21: 6421.","journal-title":"Int J Mol Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneph.2017.184","article-title":"Paradigms of acute kidney injury in the intensive care setting","volume":"14","author":"Kellum","year":"2018","unstructured":"Kellum JA and Prowle JR. Paradigms of acute kidney injury in the intensive care setting. Nat Rev Nephrol 2018; 14: 217-230.","journal-title":"Nat Rev Nephrol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41581-019-0145-4","article-title":"Obesity, kidney dysfunction and hypertension: mechanistic links","volume":"15","author":"Hall","year":"2019","unstructured":"Hall JE, do Carmo JM, da Silva AA, Wang Z and Hall ME. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol 2019; 15: 367-385.","journal-title":"Nat Rev Nephrol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1681\/ASN.2010010085","article-title":"A multi-marker approach to predict incident CKD and microalbuminuria","volume":"21","author":"Fox","year":"2010","unstructured":"Fox CS, Gona P, Larson MG, Selhub J, Tofler G, Hwang SJ, Meigs JB, Levy D, Wang TJ, Jacques PF, Benjamin EJ and Vasan RS. A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol 2010; 21: 2143-2149.","journal-title":"J Am Soc Nephrol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1097\/HJH.0b013e32834bbc8a","article-title":"Association of plasma renin activity and aldosterone-renin ratio with prevalence of chronic kidney disease: the Kaiser Permanente Southern California cohort","volume":"29","author":"Sim","year":"2011","unstructured":"Sim JJ, Shi J, Calara F, Rasgon S, Jacobsen S and Kalantar-Zadeh K. Association of plasma renin activity and aldosterone-renin ratio with prevalence of chronic kidney disease: the Kaiser Permanente Southern California cohort. J Hypertens 2011; 29: 2226-2235.","journal-title":"J Hypertens"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1097\/HJH.0b013e328354f65b","article-title":"Plasma renin activity and the aldosterone-to-renin ratio are associated with the development of chronic kidney disease: the Ohasama Study","volume":"30","author":"Terata","year":"2012","unstructured":"Terata S, Kikuya M, Satoh M, Ohkubo T, Hashimoto T, Hara A, Hirose T, Obara T, Metoki H, Inoue R, Asayama K, Kanno A, Totsune K, Hoshi H, Satoh H, Sato H and Imai Y. Plasma renin activity and the aldosterone-to-renin ratio are associated with the development of chronic kidney disease: the Ohasama Study. J Hypertens 2012; 30: 1632-1638.","journal-title":"J Hypertens"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1471-2369-15-44","article-title":"Aldosterone and glomerular filtration--observations in the general population","volume":"15","author":"Hannemann","year":"2014","unstructured":"Hannemann A, Rettig R, Dittmann K, Völzke H, Endlich K, Nauck M and Wallaschofski H. Aldosterone and glomerular filtration--observations in the general population. BMC Nephrol 2014; 15: 44.","journal-title":"BMC Nephrol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1161\/HYPERTENSIONAHA.114.03936","article-title":"Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease","volume":"65","author":"Buglioni","year":"2015","unstructured":"Buglioni A, Cannone V, Cataliotti A, Sangaralingham SJ, Heublein DM, Scott CG, Bailey KR, Rodeheffer RJ, Dessì-Fulgheri P, Sarzani R and Burnett JC Jr. Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease. Hypertension 2015; 65: 45-53.","journal-title":"Hypertension"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1530\/EJE-19-0047","article-title":"Renal impairment is closely associated with plasma aldosterone concentration in patients with primary aldosteronism","volume":"181","author":"Kawashima","year":"2019","unstructured":"Kawashima A, Sone M, Inagaki N, Takeda Y, Itoh H, Kurihara I, Umakoshi H, Ichijo T, Katabami T, Wada N, Ogawa Y, Kawashima J, Fujita M, Miyauchi S, Okamura S, Fukuoka T, Yanase T, Izawa S, Yoshikawa Y, Hashimoto S, Yamada M, Kai T, Suzuki T and Naruse M. Renal impairment is closely associated with plasma aldosterone concentration in patients with primary aldosteronism. Eur J Endocrinol 2019; 181: 339-350.","journal-title":"Eur J Endocrinol"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Bolignano D, Palmer SC, Navaneethan SD and Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2014; CD007004.","DOI":"10.1002\/14651858.CD007004.pub3"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Hou J, Xiong W, Cao L, Wen X and Li A. Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: a meta-analysis. Clin Ther 2015; 37: 2086-2103, e10.","DOI":"10.1016\/j.clinthera.2015.05.508"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1161\/HYPERTENSIONAHA.119.13131","article-title":"Association between acute fall in estimated glomerular filtration rate after treatment for primary aldosteronism and long-term decline in renal function","volume":"74","author":"Kobayashi","year":"2019","unstructured":"Kobayashi H, Abe M, Nakamura Y, Takahashi K, Fujita M, Takeda Y, Yoneda T, Kurihara I, Itoh H, Tsuiki M, Wada N, Ichijo T, Katabami T, Ogawa Y, Kawashima J, Yoshimoto T, Sone M, Inagaki N, Watanabe M, Kamemura K, Matsuda Y, Izawa S, Tanabe M, Tanabe A, Suzuki T and Naruse M; JPAS\/JRAS Study Group. Association between acute fall in estimated glomerular filtration rate after treatment for primary aldosteronism and long-term decline in renal function. Hypertension 2019; 74: 630-638.","journal-title":"Hypertension"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40265-019-01073-5","article-title":"Esaxerenone: first global approval","volume":"79","author":"Duggan","year":"2019","unstructured":"Duggan S. Esaxerenone: first global approval. Drugs 2019; 79: 477-481.","journal-title":"Drugs"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study)","volume":"75","author":"Ito","year":"2020","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M and Yamakawa S. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). Hypertension 2020; 75: 51-58.","journal-title":"Hypertension"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","unstructured":"Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y and Sawanobori T. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol 2020; 15: 1715-1727.","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study","volume":"25","author":"Wada","year":"2021","unstructured":"Wada T, Inagaki M, Yoshinari T, Terata R, Totsuka N, Gotou M and Hashimoto G. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study. Clin Exp Nephrol 2021; 25: 120-130.","journal-title":"Clin Exp Nephrol"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Bamberg K, Johansson U, Edman K, William-Olsson L, Myhre S, Gunnarsson A, Geschwindner S, Aagaard A, Björnson Granqvist A, Jaisser F, Huang Y, Granberg KL, Jansson-Löfmark R and Hartleib-Geschwindner J. Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PLoS One 2018; 13: e0193380.","DOI":"10.1371\/journal.pone.0193380"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/jhh.2015.119","article-title":"Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis","volume":"30","author":"Takahashi","year":"2016","unstructured":"Takahashi S, Katada J, Daida H, Kitamura F and Yokoyama K. Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis. J Hum Hypertens 2016; 30: 534-542.","journal-title":"J Hum Hypertens"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1161\/HYPERTENSIONAHA.121.17005","article-title":"Cardiovascular protection with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in chronic kidney disease: a milestone achieved","volume":"77","author":"Sarafidis","year":"2021","unstructured":"Sarafidis P, Papadopoulos CE, Kamperidis V, Giannakoulas G and Doumas M. Cardiovascular protection with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in chronic kidney disease: a milestone achieved. Hypertension 2021; 77: 1442-1455.","journal-title":"Hypertension"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM and Bakris GL; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022; 43: 474-484.","journal-title":"Eur Heart J"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/8\/ajtr0156540.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:55:13Z","timestamp":1766022913000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/8\/ajtr0156540.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":55,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/nrgg6465","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}